Plasma kinetics of procarbazine and azo-procarbazine in humans

Anti-Cancer Drugs

Volumn 17, Issue 1, 2006, Pages 75-80

  Preiss, Rainer ^a   Baumann, Frank ^a   Regenthal, Ralf ^a   Matthias, Michael ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Rehabilitation Centre   (Germany)

Author keywords

Azo procarbazine; Human; Pharmacokinetics; Procarbazine

Indexed keywords

AZOPROCARBAZINE; DRUG METABOLITE; ONDANSETRON; PROCARBAZINE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR; ULTRAVIOLET SPECTROSCOPY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PROCARBAZINE;

EID: 33646089870     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000181591.85476.aa     Document Type: Article

References (27)

1. Friedman HS, Averbuch SD, Kurtzberg J. Nonclassic alkylating agents. In: Chabner BA, Longo DL (editors): Cancer chemotherapy and biotherapy. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 415.
2. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPPABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348:2386-2395.
3. Massoud M, Armand JP, Ribrag V. Procarbazine in haematology: an old drug with a new life? Eur J Cancer 2004; 40:1924-1927.
4. Erikson JM, Tweedie DJ, Ducore JM, Prough RA. Cytotoxicity and DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cells. Cancer Res 1989; 49:127-133.
5. Kreis W. Metabolism of an antineoplastic methylhydrazine derivative in a P815 mouse neoplasm. Cancer Res 1970; 30:82-89.
6. Newell D, Gescher A, Harland S, Ross D, Rutty C. N-Methyl antitumor agents. Cancer Chemother Pharmacol 1987; 19:91-102.
7. Prough RA, Tweedie DJ. Procarbazine. In: Powis G, Prough RA (editors): Metabolism and action of anticancer drug. New York: Taylor & Francis; 1987. pp. 29-47.
8. Reid JM, Kuffel MJ, Miller JK, Rios R, Ames MM. Metabolic activation of dacarbazine by human cytochromes p450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res 1999; 5:2192-2197.
9. Saleem A, Brown GD, Brady F. Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 2003; 63:2409-2415.
10. 6-alkylguanine-DNA alkyltransferase and sensitivity to PCR in human brain tumor xenografts. J Neurosurg 1989; 70:573-577.
11. Coomes MW, Prough RA. The mitochondrial metabolism of 1,2-disubstituted hydrazines, procarbazine and 1,2-dimethylhydrazine. Drug Metab Disp 1983; 11:550-555.
12. Dunn DL, Lubet RA, Prough RA. Oxidative metabolism of N-isopropyl-α-(2-methylhydrazino)-p-toluamide hydrochloride (procarbazine) by rat liver microsomes. Cancer Res 1979; 39:4555-4563.
13. Erikson JM, Prough RA. Oxidative metabolism of some hydrazine derivatives by rat liver and lung tissue fractions. J Biochem Toxicol 1986; 1:41-52.
14. Weinkam RJ, Shiba DA. Metabolic activation of procarbazine. Life Sci 1978; 22:937-946.
15. Prough RA, Brown MI, Dannan GA, Guengerich FP. Major isozymes of rat liver microsomal cytochrome P-450 involved in the N-oxidation of N-isopropyl-α-(2-methylazo)-p-toluamide, the azo derivative of procarbazine. Cancer Res 1984; 44:543-548.
16. Wiebkin P, Prough RA. Oxidative metabolism of N-isopropyl-α-(2-methylazo)-p-toluamide (azoprocarbazine) by rodent liver microsomes. Cancer Res 1980; 40:3524-3529.
17. Moloney SJ, Wiebkin P, Cummings SW, Prough RA. Metabolic activation of the terminal N-methyl group of N-isopropyl-α-(2-methylhydrazino)-p-toluamide hydrochloride (procarbazine). Carcinogenesis 1985; 6:397-401.
18. Schwartz DE, Bollag W, Obrecht P. Distribution and excretion studies of procarbazine in animals and man. Arzneimittelforschung 1967; 17:1389-1393.
19. Swaffar DS, Harker WG, Pomerantz SC, Lim HK, Yost GS. Isolation, purification, and characterization of two new chemical decomposition products of methylazoxyprocarbazine. Drug Met Dispos 1992; 20:632-642.
20. Swaffar DS, Pomerantz SC, Harker WG, Yost GS. Non-enzymatic activation of procarbazine to active cytotoxic species. Oncol Res 1992; 4:49-58.
21. Tweedie DJ, Erikson JM, Prough RA. Cytosolic enzymes mediate the metabolism of the azoxy isomers of the anticancer drug, procarbazine. Proc Am Ass Cancer Res 1987; 28:521.
22. Swaffar DS, Horstman MG, Jaw J-Y, Thrall BD, Meadows GG, Harker WG, et al. Methylazoxyprocarbazine, the active metabolite responsible for anticancer activity of procarbazine against L1210 leukemia. Cancer Res 1989; 49:2442-2447.
23. He X, Batchelor TT, Grossmann S, Supko JG. Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry. J Chromatogr B 2004; 799:281-291.
24. Raaflaub J, Schwartz DE. (1965). On the metabolism of a cytostatic methylhydrazine derivative (Natulan). Experentia 1965; 21:44-45.
25. Oliverío VT, Danham C, DeVita VT, Kelly MG. Some pharmacologic properties of a new antitumor agent N-isopropyl-β-(2-methylhydrazino)-p-toluamide, hydrochloride (NSC-77213). Cancer Chemother Rep 1964; 42:1-7.
26. Shiba DA, Weinkam RJ. Quantitative analysis of procarbazine, procarbazine metabolites and chemical degradation products with application to pharmacokinetic studies. J Chromatogr B 1982; 229:397-407.
27. Gorsen RM, Weiss AJ, Manthei RW. Analysis of procarbazine and metabolites by gas chromatography-mass spectrometry. J Chromatogr 1980; 221:309-318.